<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01607528</url>
  </required_header>
  <id_info>
    <org_study_id>PIC-2010</org_study_id>
    <nct_id>NCT01607528</nct_id>
  </id_info>
  <brief_title>Influence of Probiotics on Infections in Cirrhosis</brief_title>
  <acronym>PIC</acronym>
  <official_title>Probiotic Modulation of Gut Microflora in Cirrhosis: Influence on Immune Function and Infections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Graz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Austrian Science Fund (FWF)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of Graz</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Liver cirrhosis is the 10th most common cause of death in the western world. Infection is the
      most common precipitant of deterioration of liver function in cirrhosis. Endotoxin, derived
      from gram-negative organisms in the gut, can enter the circulation due to increased gut
      permeability and contributes to neutrophil dysfunction, infection risk and mortality in
      alcoholic cirrhotics. As probiotics decrease gram-negative organisms in the gut and/or
      decrease gut permeability, the investigators hypothesize that probiotic treatment would
      restore neutrophil function and prevent infection in alcoholic cirrhosis.

      The investigators hypothesize that administration of a probiotic mixture in patients with
      liver cirrhosis will improve innate immune function through alteration of the gut bacterial
      flora and gut barrier integrity.

      The aim of this randomised, double-blinded placebo-controlled study is to assess whether food
      supplementation with probiotic mixture improves neutrophil phagocytic capacity in patients
      with cirrhosis and decreases the incidence of significant infections.

      92 patients with alcoholic cirrhosis will be included according to a sample size calculation
      from preliminary data. Patients will be randomized in two groups: Group 1 receives a
      probiotic mixture Group 2 receives a similar looking and tasting placebo without bacteria.
      The recruited patients will be treated for 6 months. Besides routine clinical and laboratory
      assessments, neutrophil function, toll-like receptor expression, endotoxin levels, bacterial
      DNA, cytokine levels, albumin oxidation, gut permeability and analysis of gut microflora will
      be performed. Furthermore nutritional status and quality of life will be assessed.

      Primary endpoints will be neutrophil phagocytosis. Secondary endpoints will be significant
      infection, neutrophil oxidative burst, neutrophil toll-like receptor expression, endotoxin
      levels, bacterial DNA; cytokine levels, albumin oxidation, gut barrier function and bacterial
      flora, nutritional status and quality of life.

      If our hypothesis holds true, probiotics will provide an easily applicable and cost effective
      method to improve immune function and to prevent infection in liver cirrhosis. It is possible
      that this can improve survival of patients with liver cirrhosis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in neutrophil phagocytic capacity</measure>
    <time_frame>Change from baseline to 6 months</time_frame>
    <description>Percentage of neutrophil granulocytes showing phagocytosis of FITC (fluorescein isothiocyanate) -labelled E.coli bacteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of clinically significant infections</measure>
    <time_frame>during 12 months</time_frame>
    <description>Occurence of infections that require specific treatment and/or hospitalisation during the study period of 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>endotoxin levels</measure>
    <time_frame>0, 6, 12 months</time_frame>
    <description>Endotoxin in serum (EU/ml)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>neutrophil oxidative burst</measure>
    <time_frame>0, 6, 12 months</time_frame>
    <description>percentage of neutrophil granulocytes showing oxidative burst with and without stimulation and mean fluorescence activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>neutrophil toll like receptor expression</measure>
    <time_frame>0, 6, 12 months</time_frame>
    <description>percentage of neutrophil granulocytes showing TLR (Toll-like receptor) 2, TLR4 or TLR9 expression and mean fluorescence activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>albumin oxidation</measure>
    <time_frame>0, 6, 12 months</time_frame>
    <description>oxidative status of albumin in the plasma (percentage of (human mercaptalbumin) HMA, (human non-mercaptalbumin) HNA1 and HNA2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>inflammatory response</measure>
    <time_frame>0, 6, 12 months</time_frame>
    <description>elevation of one or more inflammatory markers: C reactive protein (mg/ml), lipopolysaccharide binding protein (ng/ml), soluble CD (cluster of differentiation) 14 (ng/ml)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bacterial flora</measure>
    <time_frame>0, 6, 12 months</time_frame>
    <description>isolation of bacterial DNA and sequencing the gut microbiome from stool and duodenal aspirate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>0, 6, 12 months</time_frame>
    <description>(short form) SF-36 questionaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>nutritional status</measure>
    <time_frame>0,6, 12 months</time_frame>
    <description>subjective global assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in gut permeability over time</measure>
    <time_frame>0, 6, 12 months</time_frame>
    <description>elevated lactulose mannitol ratio, elevated zonulin</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">92</enrollment>
  <condition>Liver Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Probiotic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>6 g of Winclove-849 containing Bifidobacterium bifidum W23, Bifidobacterium lactis W52, Lactobacillus acidophilus W37, Lactobacillus brevis W63, Lactobacillus casei W56, Lactobacillus salivarius W24, Lactococcus lactis W19, Lactococcus lactis W58 at a concentration of 2.5 x 10E9 cfu/g per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A similar looking and tasting powder</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Winclove-849</intervention_name>
    <description>6 g of Winclove-849 containing Bifidobacterium bifidum W23, Bifidobacterium lactis W52, Lactobacillus acidophilus W37, Lactobacillus brevis W63, Lactobacillus casei W56, Lactobacillus salivarius W24, Lactococcus lactis W19, Lactococcus lactis W58 at a concentration of 2.5 x 109 cfu/g</description>
    <arm_group_label>Probiotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>A similar looking and tasting powder with no active substances</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: â€¢ Patients aged between 18-80 years

          -  Clinical and radiological evidence of cirrhosis, and/or biopsy proven liver cirrhosis
             of any cause

          -  Informed consent

        Exclusion Criteria:

          -  Child-Pugh score &gt; 11

          -  Abstinence from alcohol for &lt; 2 weeks at the time of screening for inclusion

          -  Clinical evidence of active infection

          -  Antibiotic treatment within 7 days prior to enrolment

          -  Gastrointestinal haemorrhage within previous 2 weeks

          -  Use of immunomodulating agents within previous month (steroids etc.)

          -  Use of proton pump inhibitors for preceding two weeks

          -  Concomitant use of supplements (pre-, pro-, or synbiotics) likely to influence the
             study

          -  Renal failure (such as hepatorenal syndrome), creatinine &gt;1.7 mg/dL

          -  Hepatic encephalopathy II to IV

          -  Pancreatitis

          -  Other organ failure

          -  Hepatic or extra-hepatic malignancy

          -  Pregnancy

          -  Presumed non-compliance to the study medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vanessa Stadlbauer-KÃ¶llner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Graz</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Internal Medicine, Medical University of Geraz</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2012</study_first_submitted>
  <study_first_submitted_qc>May 24, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 30, 2012</study_first_posted>
  <last_update_submitted>May 4, 2016</last_update_submitted>
  <last_update_submitted_qc>May 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

